CIN 105
Alternative Names: CIN-105Latest Information Update: 28 Dec 2021
At a glance
- Originator CinRx Pharma
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 28 Nov 2017 Preclinical trials in Cardiovascular disorders in USA (unspecified route) before November 2017
- 28 Nov 2017 CinRx plans to file an IND application for CIN 105 in first half of 2018